Procyon Corporation Faces Delays in Form 10-K Filing Due to Hurricanes Helene and Milton – 8-K SEC Filing Report

Procyon Corporation, a Colorado-based company (OTCMKTS:PCYN), has recently experienced unforeseen challenges leading to delays in the filing of its Form 10-K for the fiscal year ended June 30, 2024. As detailed in their 8-K SEC filing on October 22, 2024, the company initially filed for an extension on September 30, 2024, using Form 12b-25 due to unanticipated delays.

Subsequently, Procyon Corporation has encountered significant setbacks caused by Hurricanes Helene and Milton, which have severely impacted the company’s operations. These natural disasters resulted in prolonged power outages, affecting not only the company’s personnel but also their professional advisors. Consequently, the filing of their 10-K within the granted extended period has proven to be a challenge.

Despite the operational resilience shown by Procyon Corporation, as they have been able to maintain power and essential carrier services at their location, the disruptions caused by the hurricanes have not bypassed the company’s independent auditors. The power outages have hindered the progress of the audit process, thereby contributing to the delay in completing the mandatory filing.

In response to these circumstances, the company is actively working towards finalizing the Form 10-K report and submitting it at the earliest feasible time. Procyon Corporation remains dedicated to swiftly resolving the filing issues arising from the aforementioned challenges as detailed in their recent SEC filing.

As a part of the regulatory requirements, the Chief Financial Officer, James B. Anderson, has signed off on behalf of Procyon Corporation, indicating the company’s commitment to fulfilling its obligations despite the impediments faced.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Procyon’s 8K filing here.

About Procyon

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. It provides advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name.